Anhedonia as a basic syndrome and a target for treatment for depressive disorder-Reference-Cited by-同舟云学术

Anhedonia as a basic syndrome and a target for treatment for depressive disorder

Published:2019-10-06 Issue:3 Volume: Page:10-18
ISSN:2313-7053
Container-title:V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
language:
Short-container-title:V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

Author:

Mazo G. E.¹,Kibitov A. O.²

Affiliation:

1. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology

2. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology; V.P. Serbsky National Medical Research Center on Psychiatry and Addictions

Abstract

The article presents an analytical review aimed at determining the effect of anhedonia on the course and therapeutic prognosis of depression. Currently, there is no specific pharmacological approach to the treatment of anhedonia in depression.It is clear all antidepressants that affect the symptoms of depression in general act to a certain extent on anhedonia. Modern views on the biological mechanisms involved in the formation of anhedonia are described, on the basis of which a search for drugs with anti-anhedonic activity is possible. Vortioxetine can be considered as an antidepressant with a specific anti-anhedonic effect.

Publisher

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

Reference95 articles.

1. Депрессия и риск развития соматических заболеваний. Руководство для врачей (под редакцией Незнанов Н.Г., Мазо Г.Э., Кибитов А.О.) — М. Спец. Изд-во мед. кн., 2018; 248. [Depressiya i risk razvitiya somaticheskikh zabolevani. I. Rukovodstvo dlya vrachei (pod redaktsiei Neznanov N.G., Mazo G.E., Kibitov A.O.) — M. Spets. Izdatel’stvo med.kn., 2018; 248.] (In Russ.)

2. Мазо Г.Э., Незнанов Н.Г. Депрессивное расстройство/– М. ГЭОТАР–Медиа, Москва. — 2018. — 112с. (Серия «Библиотека врача-специалиста») [Mazo G.E., Neznanov N.G. Depressivnoe rasstroistvо. — M. GEHOTAR–MediA, Moskvа. — 2018. — 112s. (Seriya «Biblioteka vracha-spetsialista»)] (In Russ.)

3. Незнанов Н.Г., Мазо Г.Э., Рукавишников Г.В. Влияние антидепрессантов на когнитивные функции пациентов с депрессивным расстройством. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2015; 3:75–82. [Neznanov N.G., Mazo G.E., Rukavishnikov G.V. Vliyanie antidepressantov na kognitivnye funktsii patsientov s depressivnym rasstroistvoм. // Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. BekhterevA. 2015; 3:75-82] (InRuss.)

4. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence. 2012; 6:369–388. DOI: 10.2147/PPA.S29716

5. Ameli R, Luckenbaugh DA., Gould NF., Kathleen Holmes M, Lally N, Ballard ED, & ZarateCA. SHAPS-C: The Snaith-Hamilton pleasure scale modified for clinician administration. PeerJ. 2014; 1:e429. https://doi.org/10.7717/peerj.429

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022

2. Anhedonia in Depression: Neurobiological and Genetic Aspects;Neuroscience and Behavioral Physiology;2022-01

3. Understanding of anhedonia: from traditional to phenomenological analysis of the phenomena;Neurology Bulletin;2021-12-04

4. Anhedonia in depression: neurobiological and genetic aspects;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2021